Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 2, 2015, Pages 259-262

  Sabnani, Manoj K ^a   Rajan, Robin ^a   Rowland, Bradley ^a   Mavinkurve, Vikram ^a   Wood, Laurence M ^a   Gabizon, Alberto A ^b   La Beck, Ninh M ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Angiogenesis; Immunosuppression; Liposome; Nanoparticle; Tumor growth

Indexed keywords

DISEASES; IMMUNE SYSTEM; LIPOSOMES; NANOPARTICLES; T-CELLS; TUMORS;

ANGIOGENESIS; CYTOKINE PRODUCTION; IMMUNOSUPPRESSION; LIPOSOMAL NANOPARTICLES; PATIENT SURVIVALS; TUMOR ANGIOGENESIS; TUMOR DRUG DELIVERIES; TUMOR GROWTH;

DRUG DELIVERY;

DOXORUBICIN; GAMMA INTERFERON; LIPOSOME; NANOPARTICLE; DRUG CARRIER;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; CAPILLARY DENSITY; CELL INFILTRATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOPHENOTYPING; MACROPHAGE; MOUSE; NONHUMAN; TUMOR GROWTH; ANIMAL; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

MURINAE;

ANIMALS; CELL PROLIFERATION; DRUG CARRIERS; FEMALE; HUMANS; LIPOSOMES; MICE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84922772149     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.08.010     Document Type: Article

References (10)

1. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013, 65(1):36-48.
2. Gibson J.M., Alzghari S., Ahn C., Trantham H., La-Beck N.M. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist 2013, 18(9):1022-1031.
3. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15(3):440-449.
4. Markman M., Gordon A.N., McGuire W.P., Muggia F.M. Liposomal anthracycline treatment for ovarian cancer. Semin Oncol 2004, 31(6 Suppl. 13):91-105.
5. Dobrovolskaia M.A., Germolec D.R., Weaver J.L. Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol 2009, 4(7):411-414.
6. Moghimi S.M. Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. J Control Release 2014, 190:556-562.
7. Ji H., Chang E.Y., Lin K.Y., Kurman R.J., Pardoll D.M., Wu T.C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 1998, 78(1):41-45.
8. Allavena P., Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012, 167(2):195-205.
9. Munn D.H., Mellor A.L. The tumor-draining lymph node as an immune-privileged site. Immunol Rev 2006, 213:146-158.
10. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161(2):175-187.